FDA Grants Breakthrough Therapy Designation for BrainChild Bio’s B7-H3 CAR T Cell Therapy for Incurable Pediatric Brain Tumors

BrainChild Bio, Inc. announced that the investigational B7-H3 targeting autologous CAR T cell therapy has been granted Breakthrough Therapy designation by the US FDA for the treatment of diffuse intrinsic pontine glioma.